← Leaderboards
Brian Robert Wamhoff
University Of Virginia
$12,593,470
Attributed
$12,593,470
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.2M · FY2008–18$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$12,593,470 · 10
By mechanism
R44$11,158,741 · 7
R01$930,588 · 1
R43$504,141 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Edward A Botchwey$8,169,626
- Stephen J Lewis$1,910,835
- Kevin R Lynch$18,485,029
- Maria L Sequeira Lopez$6,637,873
- Benjamin Ledford$246,958
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroResponseTechnologyPhenotypeLegal PatentBiotechnologySmall Business Innovation Research GrantCellsPharmaceutical PreparationsIn VivoDrug DiscoveryHepatocyteDrug DevelopmentLiverLettersSuccessBiologyMorphologyPhysiologicalBlood VesselsRattusMethodologyGenesGenetic
Grant awards (20)
Validation of targets for therapeutic intervention in NASH$650,969
R44 · FY2018 · DK · contact PI
Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism$390,596
R44 · FY2018 · TR · contact PI
Validation of targets for therapeutic intervention in NASH$1,211,258
R44 · FY2017 · DK · contact PI
Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism$781,186
R44 · FY2017 · TR · contact PI
Validation of a human in vitro system of hepatic steatohepatitis$1,210,475
R44 · FY2016 · DK · contact PI
Development of an iPSC-derived human hepatocyte platform for drug development.$563,284
R44 · FY2016 · GM · contact PI
Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism$433,819
R44 · FY2016 · TR · contact PI
Development of a DIVI platform for issue resolution in pre-clinical drug development.$73,603
R44 · FY2016 · GM · contact PI
Development of a human physiological multi-cellular liver platform for drug-induced liver injury and disease.$1,261,020
R44 · FY2015 · DK · contact PI
Development of an iPSC-derived human hepatocyte platform for drug development.$1,126,573
R44 · FY2015 · GM · contact PI
Development of a DIVI platform for issue resolution in pre-clinical drug development.$1,126,395
R44 · FY2015 · GM · contact PI
Development of a human physiological multi-cellular liver platform for drug-induced liver injury and disease.$463,475
R44 · FY2015 · DK · contact PI
Development of an in vitro system of human hepatic steatosis.$255,128
R43 · FY2015 · DK · contact PI
Development of an iPSC-derived human hepatocyte platform for drug development.$281,942
R44 · FY2014 · GM · contact PI
Development of an iPSC-derived human vascular system for drug discovery and devel$249,013
R43 · FY2014 · TR · contact PI
Development of a human hepatocyte predictive pharmacology and toxicology system.$1,584,146
R44 · FY2013 · DK · contact PI
Calcium-dependent Regulation of Smooth Muscle Phenotype$252,333
R01 · FY2010 · HL · contact PI
Calcium-dependent Regulation of Smooth Muscle Phenotype$252,333
R01 · FY2009 · HL · contact PI
Calcium-dependent Regulation of Smooth Muscle Phenotype$173,589
R01 · FY2009 · HL · contact PI
Calcium-dependent Regulation of Smooth Muscle Phenotype$252,333
R01 · FY2008 · HL · contact PI